Discover how stabiliser selection and concentration affect dual-drug co-suspension stability and long-acting injectables, with potential relevance for AMR.
Dual-drug long-acting injectables could offer a new approach to tackling antimicrobial resistance (AMR) by combining multiple medicines into a single sustained-release formulation.
But there are serious formulation and manufacturing challenges involved, showing why stabiliser selection, particle engineering, and physical stability will be critical to making these therapies viable.
Image
Could Dual-Drug Long-Acting Injectables Strengthen the Fight Against AMR?
Antimicrobial resistance remains one of the pharmaceutical industry’s most difficult challenges.
Treatment regimens for infections such as HIV, tuberculosis, and malaria often require multiple medicines administered over extended periods.
Maintaining consistent adherence can be difficult, particularly when treatment involves frequent dosing or complex schedules.
Missed doses and incomplete treatment can undermine therapeutic effectiveness and contribute to conditions in which resistant organisms gain an advantage.
Improving how medicines are delivered is therefore an important part of the wider AMR response.
Long-acting injectables (LAIs) offer one potential solution.
Instead of requiring patients to take medication every day, these formulations release active pharmaceutical ingredients (APIs) over an extended period. Depending on the formulation, therapeutic delivery can continue for weeks or months.
The next development is particularly interesting: Combining two active medicines into a single long-acting suspension.
This approach could simplify treatment regimens, reduce administration frequency, and improve adherence.
It could also help maintain coordinated exposure to multiple medicines, an important consideration when treating infections that require combination therapy.
However, translating this concept into a reliable pharmaceutical product requires more than simply mixing two drug compounds.
The Manufacturing Challenge of Combining Two Medicines
For successful development of dual-acting long-acting injectables, the focus has to be on manufacturing for physical stability of dual-drug co-suspensions because different stabilisers influence particle size, milling performance, and formulation stability.
A 2026 study examined three poorly soluble drug compounds: Itraconazole, carbamazepine, and cinnarizine.
Although these compounds served as model APIs rather than demonstrating a finished antimicrobial treatment, the findings offer valuable insight into the challenges of developing multi-drug injectable formulations.
The central manufacturing issue is that two medicines do not necessarily behave predictably when combined.
Each API has different physical and chemical properties. These influence how easily particles can be reduced in size, how they interact with excipients, and how they behave during storage.
A formulation that performs well with one drug may become unstable when a second compound is introduced.
For CDMOs, this creates a more demanding development environment. Formulation decisions must account for interactions between both APIs rather than treating each compound as an independent ingredient.
Reimagine AI-driven Drug Discovery with Pharma Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
Wet-Bead Milling and the Importance of Particle Engineering
The 2026 research used wet-bead milling to produce micro- and nanoscale drug particles.
This manufacturing approach reduces the size of solid drug particles suspended in a liquid. Smaller particles can support controlled drug release and improve the formulation characteristics needed for long-acting delivery.
However, reducing particle size creates a larger surface area. This increases the potential for particles to interact, aggregate, or undergo physical changes during storage.
Manufacturers therefore need stabilisers to maintain the suspension.
These excipients help protect particle surfaces and limit aggregation. Their effectiveness depends on the properties of the specific drug and the concentration used.
The researchers evaluated nine stabilisers, including poloxamers, polyvinylpyrrolidone (PVP), polysorbates, and other surfactants.
The results demonstrated substantial differences between the individual drug compounds.
Poloxamer 338 (P338) generally provided the strongest performance for itraconazole-containing suspensions.
PVP K30 performed particularly well for carbamazepine, although significant foaming created practical handling problems.
Different stabiliser concentrations produced different outcomes, with higher concentrations sometimes improving particle size reduction and sometimes making it worse.
These findings highlight an important consideration for pharmaceutical Technical Operations in that excipient selection cannot be separated from process development.
The formulation must achieve the desired particle characteristics without introducing problems that compromise manufacturing efficiency, stability, or eventual administration.
One of the most important findings was that the behaviour of a combined formulation could not be reliably predicted from the performance of its individual components.
In the carbamazepine–itraconazole combination, the particle-size characteristics generally followed those observed in itraconazole suspensions. However, changes during storage did not directly mirror either individual drug.
The cinnarizine–itraconazole combination behaved differently.
No consistent influence from either individual compound emerged, reinforcing the importance of testing each drug combination independently.
The 2026 study also identified an interesting opportunity. Some dual-drug formulations produced smaller particles than their corresponding single-drug suspensions.
This suggests that combining APIs can influence milling behaviour in ways that may benefit formulation performance.
However, smaller particles do not automatically mean a better pharmaceutical product.
The researchers found that the concentration producing the greatest particle-size reduction did not consistently deliver the best physical stability during storage.
For example, P338 provided effective particle reduction in itraconazole-containing formulations. Yet, increasing its concentration could also increase particle growth in certain co-suspensions. At 0.5% P338, the formulation achieved favourable initial particle reduction, while increasing the concentration to 1.0% improved subsequent stability.
This distinction matters for manufacturers. Optimising the manufacturing process and optimising the finished formulation are not necessarily the same.
What Does This Mean for Pharmaceutical Manufacturing?
The co-suspension findings have implications beyond laboratory formulation development. They highlight several considerations for companies exploring long-acting combination therapies.
1. Formulation development must be API-specific
Manufacturers cannot assume that an excipient concentration or stabilisation strategy will work across different drug combinations. Each formulation requires its own optimisation programme.
2. Process parameters influence product quality
Bead size, milling duration, stabiliser concentration, and processing conditions all influence particle characteristics. The 2026 research also identified excessive foaming as a significant problem with certain polymers.
Foam can interfere with milling efficiency and it can complicate particle-size measurements. In the carbamazepine formulation, PVP K30 delivered good physical stability but produced such substantial foam that syringeability was compromised.
This illustrates why laboratory performance must be assessed against practical manufacturing and administration requirements.
3. Stability testing must extend beyond particle size
A formulation may retain favourable particle characteristics but still present problems with sedimentation, redispersibility, viscosity, or injection performance.
Manufacturers need to quantify these characteristics. Future development programmes will therefore need broader testing to establish whether formulations remain suitable throughout storage and administration.
The 2026 study used dual centrifugation and wet-bead milling at laboratory scale. Industrial production will introduce additional challenges around process consistency, equipment performance, temperature control, and batch reproducibility.
These factors will require careful evaluation before the technology can progress towards commercial manufacturing.
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Image
From Formulation Research to More Effective AMR Strategies
There are important technological barriers to developing more sophisticated long-acting medicines.
The potential application in infectious diseases is nevertheless compelling. A single injectable formulation containing multiple compatible antimicrobial agents could simplify treatment and reduce the burden of repeated administration.
This is particularly relevant to conditions requiring prolonged combination therapy, where maintaining adherence remains a persistent challenge.
Pharma must also recognise that long-acting delivery systems introduce their own therapeutic considerations.
Drug-release profiles, exposure levels, compatibility between APIs, and the consequences of incomplete or uneven release will all require careful evaluation.
A successful formulation must deliver both medicines at appropriate concentrations over the intended treatment period. It must also maintain consistent quality throughout manufacturing, distribution, storage, and administration.
For manufacturing teams, this means bringing formulation scientists, process engineers, analytical specialists, and quality professionals together much earlier in development.
The opportunity is not simply to manufacture a longer-lasting injection. It is to create reliable, reproducible delivery systems that support more manageable treatment regimens without compromising therapeutic performance.
Image
The Next Manufacturing Frontier for Long-Acting Medicines?
Dual-drug co-suspensions represent an interesting direction for pharmaceutical formulation science. But combining two APIs introduces physical interactions that cannot be understood by studying each drug independently.
The next challenge is translating these findings into robust processes that can withstand scale-up, storage, and real-world administration requirements.
The potential contribution to AMR strategies will ultimately depend on clinical evidence demonstrating that these formulations can deliver effective combination therapy and improve treatment adherence.
Innovative drug delivery depends as much on manufacturing science and formulation stability as it does on the medicines themselves.
So, dual-drug co-suspensions represent a promising area of formulation research, particularly where long-acting delivery could help address the practical challenges of prolonged treatment. However, translating laboratory findings into reliable pharmaceutical products will require more than particle-size optimisation.
Formulation stability, reproducibility, dose delivery, and clinical performance must all be demonstrated.
As pharmaceutical developers continue to explore more sophisticated drug-delivery systems, understanding the interaction between active ingredients, stabilisers and manufacturing processes will be essential.
Dual-drug co-suspensions are pharmaceutical formulations containing two active pharmaceutical ingredients dispersed together in a liquid vehicle. They can be investigated as a way to deliver multiple medicines through a single administration, including in potential long-acting injectable formulations.
Why are stabilisers important in long-acting injectable formulations?
Stabilisers help control interactions between drug particles and the surrounding liquid. They can influence particle size, aggregation, and physical stability during storage. Selecting the right stabiliser and concentration is particularly important when two active ingredients are combined because each compound may respond differently.
What did a 2026 dual-drug co-suspension study discover?
This article cites a 2026 study that found that stabiliser selection and concentration influenced particle-size reduction and physical stability in different ways. Poloxamer 338 generally performed well in itraconazole-containing suspensions, while PVP K30 was more effective for carbamazepine, although foaming presented challenges. The researchers also found that co-suspension stability could not be predicted solely from the behaviour of the individual drug suspensions.
Why does particle size matter in pharmaceutical suspensions?
Particle size can influence the physical behaviour of a suspension, including its tendency to aggregate, settle or change during storage. In injectable formulations, particle characteristics may also affect handling and administration. However, particle size alone cannot establish whether a formulation will remain suitable for clinical use. Other properties, including redispersibility, viscosity, and syringeability, must also be evaluated.
Could dual-drug long-acting injectables help address antimicrobial resistance?
Long-acting combination formulations could potentially contribute to treatment strategies where prolonged drug delivery and reduced administration frequency are clinically appropriate. However, the cited 2026 study did not investigate antimicrobial drugs or measure antimicrobial resistance outcomes. Further research would be required to establish whether this formulation approach could improve antimicrobial treatment, adherence, or clinical outcomes.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
1
Why not support
Nicole Dale
by giving this content a like
Why Must Adaptive Clinical Trial Design Start With Ethics?
Adaptive clinical trial design can improve research efficiency and patient protection. Discover why ethics, statistical integrity, and evidence matter.
Foundational AI In Cell and Gene Therapy Development Success
Discover why AI in cell and gene therapy is necessary for successful development by improving drug discovery, viral vector engineering, manufacturing, and quality control.
The FDA’s new final guidance for cell and gene therapy potency assurance sets out a lifecycle, risk-based approach to product quality and manufacturing control.
Comments (0)